Cortigent, Inc.

Cortigent, Inc. is a neuromodulation medical device company developing advanced brain implant systems for treating profound blindness and stroke-related paralysis. The company's core technology comprises a proprietary data processing unit that wirelessly controls microelectronic implants containing a unique 60-electrode array positioned on the brain's surface. These electrodes deliver targeted electrical stimulation to specific brain regions to either restore visual perception or enhance motor recovery. Orion® Visual Cortical Prosthesis System is Cortigent's lead product candidate, designed to provide artificial vision to patients with nearly all forms of profound blindness, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye trauma. The Orion system builds upon the legacy of Argus® Retinal Prosthesis System (Argus II), the world's first FDA-approved device for artificial vision in retinitis pigmentosa patients. Cortigent has discontinued Argus II to focus development on Orion, which targets a substantially larger patient population. A second development program addresses motor skill recovery in stroke patients. This neurostimulation system leverages the 60-channel electrode configuration to selectively target motor cortex neurons, intended to enhance hand and arm movement recovery in partially paralyzed stroke victims undergoing rehabilitation. As of January 2026, Cortigent presented promising six-year early feasibility study results for the Orion system at the North American Neuromodulation Society conference. The company is currently a subsidiary of Vivani Medical with active clinical studies recruiting prospective participants. All devices remain in clinical development or early-stage commercialization phases.